Alterity Therapeutics (ATHE) Capital Expenditures (2010 - 2019)

Alterity Therapeutics' Capital Expenditures history runs 7 years deep, the most recent figure standing at -$5123.2 for Q4 2019.

• On a quarterly basis, Capital Expenditures fell 118.19% year-over-year to -$5123.2 in Q4 2019; TTM through Dec 2019 was -$26661.1, a 100.0% increase from a year earlier, with the FY2024 full-year figure at -$5722.0, changed N/A from the prior year.
• Capital Expenditures retreated to -$5123.2 in Q4 2019 per ATHE's latest filing, from -$2348.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at -$2348.0 in Q4 2018 and bottomed at -$16622.8 in Q4 2016.
• The 4-year median for Capital Expenditures is -$3845.1 (2017), against an average of -$6665.3.
• Across the five-year window, Capital Expenditures jumped 84.56% in 2017 and sank 118.19% in 2019, its largest moves.
• Year by year, Capital Expenditures stood at -$16622.8 in 2016, then soared by 84.56% to -$2567.1 in 2017, then gained by 8.53% to -$2348.0 in 2018, then tumbled by 118.19% to -$5123.2 in 2019.
• Per Business Quant, the three latest ATHE Capital Expenditures figures stand at -$5123.2 (Q4 2019), -$2348.0 (Q4 2018), and -$2567.1 (Q4 2017).